Michael D. Witzeman Sells 735 Shares of Chemed Co. (CHE) Stock

Chemed Co. (NYSE:CHE) VP Michael D. Witzeman sold 735 shares of Chemed stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $328.00, for a total value of $241,080.00. Following the transaction, the vice president now owns 4,000 shares in the company, valued at $1,312,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Shares of Chemed stock opened at $329.28 on Friday. The stock has a market capitalization of $5.21 billion, a PE ratio of 27.60, a PEG ratio of 1.85 and a beta of 1.21. Chemed Co. has a one year low of $260.03 and a one year high of $335.99. The company has a debt-to-equity ratio of 0.15, a quick ratio of 0.80 and a current ratio of 0.83.

Chemed (NYSE:CHE) last issued its quarterly earnings results on Wednesday, February 20th. The company reported $3.35 EPS for the quarter, beating analysts’ consensus estimates of $3.27 by $0.08. The company had revenue of $457.51 million for the quarter, compared to analyst estimates of $460.50 million. Chemed had a return on equity of 36.06% and a net margin of 11.53%. The company’s quarterly revenue was up 6.8% compared to the same quarter last year. During the same period in the previous year, the company posted $2.32 earnings per share. Analysts predict that Chemed Co. will post 12.77 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Friday, March 22nd. Stockholders of record on Monday, March 4th will be issued a $0.30 dividend. The ex-dividend date of this dividend is Friday, March 1st. This represents a $1.20 dividend on an annualized basis and a dividend yield of 0.36%. Chemed’s dividend payout ratio (DPR) is 10.06%.

Several research analysts have weighed in on CHE shares. Royal Bank of Canada lifted their target price on Chemed from $313.00 to $318.00 and gave the stock a “sector perform” rating in a report on Monday, February 25th. Zacks Investment Research upgraded Chemed from a “hold” rating to a “buy” rating and set a $310.00 price target on the stock in a report on Friday, January 4th.

Several institutional investors have recently modified their holdings of CHE. Norges Bank bought a new stake in shares of Chemed in the fourth quarter valued at about $43,898,000. Renaissance Technologies LLC lifted its holdings in shares of Chemed by 69.5% in the third quarter. Renaissance Technologies LLC now owns 233,690 shares of the company’s stock valued at $74,683,000 after purchasing an additional 95,790 shares in the last quarter. Allianz Asset Management GmbH increased its position in shares of Chemed by 3,298.7% in the third quarter. Allianz Asset Management GmbH now owns 51,083 shares of the company’s stock valued at $16,325,000 after acquiring an additional 49,580 shares during the last quarter. Canada Pension Plan Investment Board increased its position in shares of Chemed by 71.2% in the third quarter. Canada Pension Plan Investment Board now owns 114,000 shares of the company’s stock valued at $36,432,000 after acquiring an additional 47,400 shares during the last quarter. Finally, Rehmann Capital Advisory Group increased its position in shares of Chemed by 33,227.1% in the third quarter. Rehmann Capital Advisory Group now owns 46,658 shares of the company’s stock valued at $146,000 after acquiring an additional 46,518 shares during the last quarter. Institutional investors own 87.06% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Michael D. Witzeman Sells 735 Shares of Chemed Co. (CHE) Stock” was first published by WKRB News and is owned by of WKRB News. If you are accessing this news story on another site, it was copied illegally and reposted in violation of US & international copyright law. The original version of this news story can be accessed at https://www.wkrb13.com/2019/03/15/michael-d-witzeman-sells-735-shares-of-chemed-co-che-stock.html.

Chemed Company Profile

Chemed Corporation provides hospice and palliative care services in the United States. It operates through two segments, VITAS and Roto-Rooter. The VITAS segment offers direct medical services, as well as spiritual and emotional counseling services to terminally ill patients. This segment offers its services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers.

Further Reading: Depreciation

Insider Buying and Selling by Quarter for Chemed (NYSE:CHE)

Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.